DUKE AWARDED GRANT TO EVALUATE COMPOUND

EntreMed, a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammatory diseases, today announced that Duke University Medical Center has received a grant from the Susan G. Komen Breast Cancer Foundation to study the company's lead compound, 2ME2 (2-Methoxyestradiol or Panzem), in metastatic breast cancer. Basic, translational and clinical studies will be conducted using Panzem NCD in combination with a variety of chemotherapeutic agents to determine the effect of 2ME2 on chemotherapy resistant tumors. EntreMed will supply Panzem NCD for these studies.

Yahoo News (http://biz.yahoo.com/prnews/050629/dcw006.html?.v=17)